Hypothesis

Intermittent senolytic treatment (D+Q) combined with selective inhibition of CDK1 to preferentially eliminate G2‑arrested senescent cells, and blockade of exosome release (e.g., GW4869), will produce a greater and more durable reduction in systemic SASP burden and functional decline than D+Q alone.

Rationale

Recent single‑cell atlas data show that ~25% of cell types undergo synchronized senescence with age, and that senescent cell propagation can be induced by transplanting small numbers of senescent cells into young hosts [2]. Functional heterogeneity reveals that G2‑arrested senescent cells secrete a more potent pro‑inflammatory SASP than G1‑arrested counterparts [3]. Moreover, senescent cells communicate systemically via extracellular vesicles that carry SASP factors, mitochondrial DNA, and microRNAs, thereby inducing senescence in distant tissues [1]. Senolytics such as D+Q eliminate senescent cells by disabling anti‑apoptotic pathways, yielding multi‑organ benefits and extended survival [4], [5]. However, current regimens do not distinguish between SASP‑potent G2 cells and less inflammatory G1 cells, nor do they block the vesicular mediators that spread the senescent phenotype.

We propose that targeting the G2‑arrested subpopulation and preventing vesicle‑mediated spread will (i) remove the most inflammatory senescent cells, (ii) cut off a key route of systemic senescence propagation, and (iii) allow lower or less frequent senolytic dosing while achieving equal or superior geroprotective outcomes.

Predictions

1. In naturally aged mice, a regimen of intermittent D+Q (5 mg/kg dasatinib + 50 mg/kg quercetin) given twice monthly plus a CDK1 inhibitor (e.g., RO‑3306) at a dose that selectively affects G2 cells will reduce circulating SASP cytokines (IL‑6, TNF‑α, CXCL10) by >50% compared with D+Q alone after 8 weeks.
2. Adding an exosome release inhibitor (GW4869, 10 mg/kg i.p. three times weekly) will further decrease plasma exosomal senescence markers (e.g., p16^INK4a^ mRNA, mitochondrial DNA) and tissue senescence burden in distal organs (lung, liver) relative to D+Q+CDK1i alone.
3. Functional readouts (grip strength, treadmill endurance, frailty index) will show a significant improvement that persists for at least 4 weeks after the final treatment, exceeding the durability observed with D+Q monotherapy.
4. If the hypothesis is false, the combination will not produce additive benefits over D+Q alone, and exosome inhibition will not further lower systemic SASP or improve functional outcomes.

Experimental Design

• Animals: 20‑month‑old C57BL/6J mice, both sexes, n=12 per group.
• Groups: (1) Vehicle control; (2) D+Q intermittent (2 days on, 14 days off) × 4 cycles; (3) D+Q + CDK1 inhibitor (RO‑3306 10 mg/kg i.p. on D+Q days); (4) D+Q + GW4869; (5) D+Q + CDK1i + GW4869.
• Readouts: Plasma cytokine panel (Luminex), exosome isolation followed by qPCR for p16, SASP miRNAs, mtDNA; tissue senescence (p16^INK4a^, SA‑β‑gal) in kidney, liver, lung, spleen; functional tests (grip strength, treadmill, frailty score) at baseline, week 4, week 8, and week 12.
• Statistical analysis: Two‑way ANOVA with post‑hoc Tukey; significance set at p<0.05.

Potential Outcomes and Falsifiability

• Supportive outcome: Groups receiving CDK1i and/or GW4869 show statistically significant reductions in plasma SASP and exosomal senescence markers beyond D+Q alone, accompanied by enhanced functional recovery that lasts beyond treatment cessation. This would confirm that G2‑arrested cells and their vesicle output are key drivers of systemic aging and that targeting them amplifies senolytic efficacy.
• Falsifying outcome: No significant difference between D+Q monotherapy and any combination group in any measured parameter, or a worsening of toxicity (e.g., thrombocytopenia) without benefit, would falsify the hypothesis that selective G2 targeting or exosome blockade adds value to senolytic therapy.

By directly linking the functional heterogeneity of senescent cells, their vesicular communication, and senolytic action, this hypothesis offers a concrete, testable route to refine intermittent senolytic regimens for broader translational impact.